Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD, Inc. (NSPR) files reports with the U.S. Securities and Exchange Commission as a Nasdaq-listed medical device company focused on the CGuard® Prime carotid stent system and its proprietary MicroNet™ mesh technology. These SEC filings provide detailed information on the company’s financial condition, capital structure, clinical and regulatory milestones, and governance.
Current reports on Form 8-K frequently disclose key events such as quarterly financial results, private placement financings, warrant exercises, and updates to investor presentations. For example, a November 4, 2025 Form 8-K discusses financial and operating results for the quarter ended September 30, 2025, while a July 31, 2025 Form 8-K outlines a securities purchase agreement for a private placement of common stock and pre-funded warrants, as well as the full exercise of a series of warrants.
Filings also document important regulatory and commercial milestones. A June 24, 2025 Form 8-K reports that InspireMD received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States, and a July 9, 2025 Form 8-K references a press release announcing the U.S. commercial launch of CGuard® Prime. Other 8-Ks describe changes to the board of directors, including the appointment of independent directors and audit committee chairs, and amendments that specify committee assignments.
On this page, users can review InspireMD’s Forms 8-K and related exhibits, along with other periodic reports when available. Stock Titan adds AI-powered summaries that explain the main points of lengthy filings, highlight material agreements and capital-raising terms, and surface notable disclosures about clinical and regulatory developments. Investors and researchers can use these NSPR filings to understand how InspireMD reports its progress in carotid stenting, manages its capital resources, and addresses the risks and uncertainties outlined in its forward-looking statements.
InspireMD, Inc. entered a new Equity Distribution Agreement with BTIG, LLC allowing it to sell, from time to time at its option, up to $75,000,000 of common shares in an at-the-market offering under its existing Form S-3 registration.
BTIG will act as sales agent and may receive a commission of up to 3.0% of gross proceeds. InspireMD currently plans to use any net proceeds for operations, including research and development, sales and marketing, working capital and other general corporate purposes. On the same date, the company terminated its prior at-the-market equity distribution agreement with Piper Sandler, under which 1,361,519 shares had been sold, and incurred no termination penalties.
InspireMD, Inc. is offering up to $75,000,000 of common stock for sale from time to time under an Equity Distribution Agreement with BTIG, LLC acting as sales agent.
The shares will be sold as an “at the market offering” (Rule 415(a)(4)) and may be sold directly on Nasdaq or by other lawful methods. The prospectus supplement illustrates up to 90,702,092 shares assuming aggregate sales of $75,000,000 at an assumed price of $1.59 per share. Shares outstanding were 43,532,281 as of December 31, 2025. BTIG’s commission is up to 3.0% of gross proceeds. Net proceeds are intended for operations, including research and development, sales and marketing, working capital and general corporate purposes.
InspireMD, Inc. is a medical device company focused on treating carotid artery disease using its proprietary MicroNet mesh–based CGuard stent platform. The company now sells CGuard EPS in over 30 countries and, after FDA premarket approval of CGuard Prime on June 23, 2025, began U.S. commercialization through a direct sales force.
The 10-K highlights strong clinical data from multiple trials, including the C-GUARDIANS pivotal study, showing low rates of stroke, myocardial infarction, and restenosis, and an estimated addressable market of about $1.3 billion and total available market of about $9.3 billion. Strategy centers on a “stent-first” approach, expanding TCAR and acute stroke indications, and growing U.S. and international presence.
Key risks include a history of recurring losses and negative operating cash flows, substantial doubt about the company’s ability to continue as a going concern, the need to raise additional capital, intense competition from large device makers, reliance on a single manufacturing facility, and ongoing regulatory and reimbursement uncertainties, including maintaining Nasdaq listing compliance.
InspireMD reported strong 2025 revenue growth but widening losses as it invests in its U.S. launch. Total revenue rose to $9.0 million in 2025, up 28% from $7.0 million in 2024, with fourth quarter revenue of $3.1 million increasing 62% year over year.
Gross margin improved as higher‑margin U.S. sales grew, with Q4 gross profit reaching $1.2 million, or 37.5% of revenue, versus 24.1% a year earlier. However, full‑year operating expenses climbed to $52.3 million from $35.0 million, reflecting expanded U.S. commercial headcount and infrastructure.
Net loss widened to $48.8 million in 2025, compared with $32.0 million in 2024, even as cash and marketable securities increased to $54.2 million as of December 31, 2025 from $34.6 million a year earlier. For 2026, management expects revenue of $13 million to $15 million, implying approximately 45% to 65% growth over 2025.
InspireMD, Inc. reported that it has provided a notice of dismissal to Chief Operating Officer Andrea Tommasoli, who is employed by subsidiary InspireMD Ltd. under a French-law Employment Agreement dated November 2, 2020.
The dismissal is subject to a six-month notice period and compliance with French labor laws. Tommasoli is released from his duties effective April 1, 2026, but will continue to receive base salary through the end of the notice period and health and provident benefits under French law for up to 12 months.
He will also receive severance pay of approximately €61,000 gross plus accrued unused paid leave. Subject to applicable French law, his last day of employment is expected to be September 1, 2026.
InspireMD director Paul Stuka reported an open-market purchase of 2,710 shares of InspireMD common stock. The transaction occurred on December 9, 2025 at a weighted average price of $1.81 per share, in multiple trades between $1.80 and $1.81. Following this purchase, Stuka directly owned 391,628 shares. The Form 4/A amends a prior filing solely to correct the number of shares shown in one column, with no other changes.
InspireMD, Inc. (NSPR) received a Schedule 13G filing from institutional investor affiliates of OrbiMed, reporting significant passive ownership of its common stock. As of 12/31/2025, OrbiMed Advisors LLC reported beneficial ownership of 3,133,405 shares, representing 7.4% of InspireMD’s common stock.
OrbiMed Capital GP IX LLC separately reported beneficial ownership of 2,878,704 shares, or 6.8% of the class. Both entities report only shared power to vote and dispose of these shares, with no sole voting or dispositive power, and certify the holdings are not for the purpose of influencing control of InspireMD.
InspireMD, Inc. (NSPR) received an updated ownership report from Rosalind-related investors on an amended Schedule 13G as of 12/31/2025. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., and portfolio managers Steven Salamon and Gilad Aharon collectively report beneficial ownership of 3,905,743 common shares, or 9.2% of InspireMD’s common stock, based on 42,370,995 shares outstanding as of November 10, 2025.
The group also holds 7,081,361 common shares issuable upon exercise of pre-funded and standard warrants, but these cannot currently be exercised because of a 9.99% “blocker” that prevents exercises which would push holdings above that level. The reporting persons state that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of InspireMD.
InspireMD Chief Commercial Officer Shane Thomas Gleason reported a series of automatic stock sales to cover taxes on vested restricted stock. Between mid-January and early February 2026, he sold multiple small blocks of InspireMD common stock under a pre-established sell-to-cover instruction.
The filing explains that these transactions were required to satisfy tax withholding obligations tied to restricted stock vesting and were executed pursuant to an automatic sales instruction letter adopted on November 25, 2024, rather than being discretionary trades. After the most recent sale, Gleason beneficially owned 1,139,177 shares of InspireMD common stock directly.
Aberdeen Group plc and abrdn Inc. report a significant institutional holding in InspireMD, Inc. They beneficially own 3,173,364 shares of InspireMD common stock, representing 7.49% of the class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority.
The firms state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of InspireMD. abrdn Inc. holds the position on behalf of underlying clients that own 5% or more of this security class.